ArticleJournal of medical case reports2025
Analysis of different prognoses in two hepatocellular carcinoma patients with pathological complete response after conversion therapy: a case report.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma is a common lethal malignancy, with most patients diagnosed at an advanced stage, precluding surgical resection. Conversion therapy combining locoregional and systemic treatments has emerged as an effective approach to downstage tumors and facilitate curative-intent surgery. However, the prognosis after conversion therapy varies significantly among patients. Case reports can reveal differences in clinical outcomes following conversion therapy and their underlying causes. CASE PRESENTATION: Here, we report two patients of advanced hepatocellular carcinoma with vascular invasion who underwent conversion therapy consisting of hepatic artery infusion chemotherapy, transarterial chemoembolization, targeted therapy (lenvatinib), and immunotherapy (programmed cell death protein 1 inhibitors). Both patients experienced significant tumor shrinkage, allowing successful surgical resection, and postoperative pathology confirmed pathological complete response. However, their long-term prognoses differed markedly: one patient, a 38-year-old male patient of Asian descent, remained recurrence-free for over 4 years, while the other patient, a 47-year-old male patient of Asian descent, experienced recurrence within 11 months after surgery. These differences might be associated with adverse baseline features and imaging findings, including preoperative portal vein tumor thrombus, markedly elevated alpha-fetoprotein, insufficient tumor shrinkage despite radiological complete response, and the coexistence of intrahepatic/extrahepatic bile duct stones, all of which may have predisposed the second patient to early recurrence.
conclusionAlthough conversion therapy can significantly downstage advanced hepatocellular carcinoma and allow curative-intent resection, the variability in long-term outcomes highlights the critical importance of preoperative tumor characteristics and treatment response assessment. Optimizing patient selection and enhancing postoperative surveillance and intervention strategies may improve long-term outcomes for these patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.